Media stories about National Research (NASDAQ:NRCIA) have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. National Research earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned press coverage about the business services provider an impact score of 45.3562768589964 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news stories that may have impacted Accern Sentiment’s scoring:
- National Research (NRCIA) Downgraded by Zacks Investment Research to “Hold” (americanbankingnews.com)
- John N. Nunnelly Sells 3,000 Shares of National Research Co. (NRCIA) Stock (americanbankingnews.com)
- National Research (NRCIA) Upgraded to “Buy” at ValuEngine (americanbankingnews.com)
- National Research (NRCIA) Upgraded to Buy at Zacks Investment Research (americanbankingnews.com)
- National Research Co. (NRCIA) Receives Average Rating of “Hold” from Brokerages (americanbankingnews.com)
NASDAQ NRCIA opened at $31.20 on Friday. The firm has a market capitalization of $762.26, a P/E ratio of 53.79 and a beta of 1.68. National Research has a twelve month low of $20.19 and a twelve month high of $41.99.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 13th. Investors of record on Friday, March 30th will be issued a $0.10 dividend. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $0.40 dividend on an annualized basis and a yield of 1.28%. National Research’s payout ratio is 68.97%.
Several brokerages have recently issued reports on NRCIA. Zacks Investment Research downgraded shares of National Research from a “buy” rating to a “hold” rating in a report on Thursday, March 29th. BidaskClub upgraded shares of National Research from a “hold” rating to a “buy” rating in a report on Friday, January 26th.
In other news, major shareholder Amandla Mk Trust purchased 5,494,440 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were acquired at an average price of $19.31 per share, with a total value of $106,097,636.40. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John N. Nunnelly sold 2,383 shares of the company’s stock in a transaction on Friday, March 16th. The shares were sold at an average price of $31.74, for a total transaction of $75,636.42. Following the sale, the director now directly owns 31,842 shares in the company, valued at approximately $1,010,665.08. The disclosure for this sale can be found here. Insiders sold 6,870,104 shares of company stock valued at $164,329,548 over the last 90 days. 5.70% of the stock is currently owned by company insiders.
About National Research
National Research Corporation, doing business as NRC Health, is a provider of analytics and insights for healthcare providers, payers and other healthcare organizations. The Company operates through six segments: Experience, The Governance Institute, Market Insights, Transparency, National Research Corporation Canada and Connect.
Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.